Wikipedia
For a decade, leading academic institutes and their associated companies fought a bruising, headline-grabbing fight over who held patent rights to CRISPR-Cas9, the revolutionary genome editing tool.
Editas Medicine, the winner of that battle in the U.S., will now cash in.
advertisement
Vertex Pharmaceuticals and Editas announced Wednesday that Vertex will pay Editas $50 million, along with a series of annual payments through 2034, in exchange for rights to use CRISPR-Cas9 in Casgevy, the sickle cell therapy approved last week.
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log In
Previous article：
Patients, doctors are clashing about side effects of hormonal birth control
Next article： Drug repurposing or repositioning? The language matters
Next article： Drug repurposing or repositioning? The language matters
